NASDAQ
13.10.25 | 22:00
1,500 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | TELA Bio appoints healthcare leader Betty Jo Rocchio to board | 1 | Investing.com | ||
| Do | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| Do | TELA Bio, Inc.: TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran | 26 | GlobeNewswire (Europe) | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 12.08. | Tela Bio reiterates $85M-$88M 2025 revenue target as international expansion accelerates | 1 | Seeking Alpha | ||
| 11.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.08. | TELA Bio GAAP EPS of -$0.22, revenue of $20.2M | 4 | Seeking Alpha | ||
| 11.08. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | TELA Bio, Inc.: TELA Bio Reports Second Quarter 2025 Financial Results | 128 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 08.08. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 150 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 21.07. | TELA Bio, Inc.: TELA Bio to Announce Second Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 06.06. | TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 165 | GlobeNewswire (Europe) | MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 03.06. | TELA Bio, Inc.: TELA Bio Announces European Commercial Launch of OviTex Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair | 124 | GlobeNewswire (Europe) | MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 02.06. | TELA Bio ernennt Jeffrey Blizard zum neuen Präsidenten | 2 | Investing.com Deutsch | ||
| 02.06. | TELA Bio, Inc.: TELA Bio Appoints Jeffrey Blizard as President | 163 | GlobeNewswire (Europe) | MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 30.05. | TELA Bio, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 20.05. | Piper Sandler maintains TELA Bio stock at Neutral with $2 target | 2 | Investing.com | ||
| 09.05. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 125 | GlobeNewswire (Europe) | MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 09.05. | TELA Bio GAAP EPS of -$0.25 misses by $0.05, revenue of $18.5M beats by $1.15M | 2 | Seeking Alpha | ||
| 08.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 23,790 | +3,59 % | Moderna, Inc.: Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress | mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,095 | +0,32 % | Sarepta-Aktie: Zurück zu altem Glanz? | Die Aktie von Sarepta Therapeutics steht wieder im Fokus der Biotech-Anleger. Nach einem starken Umsatzwachstum und hohen Erwartungen an neue Gentherapien fragen sich viele, ob das Papier seinen nächsten... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,357 | +10,61 % | PacBio selected for Korean Pangenome Reference Project | ||
| MYRIAD GENETICS | 6,450 | -2,27 % | Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy | SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH)... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,180 | -1,80 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,940 | +2,08 % | CytomX: Führt CX-2051 zur Übernahme? | Die Aktie des US-Biotechunternehmens CytomX Therapeutics, einer unserer immer wieder äußerst lukrativen Dauerbrenner in der Community, hat in diesem Jahr deutlich an Dynamik gewonnen. Nach überzeugenden... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 5,850 | +0,78 % | Vir Biotechnology stock rises as company doses first patient in prostate cancer trial | ||
| RAPT THERAPEUTICS | 22,800 | -0,87 % | Barclays initiates Rapt Therapeutics stock with Overweight rating on RPT904 potential | ||
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm plc - 6-K, Report of foreign issuer | ||
| AVIDITY BIOSCIENCES | 48,960 | -1,57 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,550 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| NUVALENT | 89,75 | +1,79 % | Nuvalent präsentiert neue Daten zu HER2-Inhibitor auf Krebskonferenz | ||
| TARSUS PHARMACEUTICALS | 70,34 | +0,31 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| ARCELLX | 86,23 | -0,65 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| QIAGEN | 40,955 | +1,20 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.